The Ensign Group, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US29358P1012
USD
175.36
-1.73 (-0.98%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

181.64 k

Shareholding (Mar 2025)

FII

9.04%

Held by 164 FIIs

DII

35.17%

Held by 63 DIIs

Promoter

0.01%

How big is The Ensign Group, Inc.?

22-Jun-2025

As of Jun 18, The Ensign Group, Inc. has a market capitalization of $9.28 billion, with net sales of $4.42 billion and a net profit of $309.85 million for the latest four quarters. The balance sheet as of Dec'24 shows shareholder's funds of $1.84 billion and total assets of $5.20 billion.

As of Jun 18, The Ensign Group, Inc. has a market capitalization of 9,277.82 million, categorizing it as a Mid Cap company.<BR><BR>As of Jun 18, the company reported net sales of 4,423.36 million and a net profit of 309.85 million for the latest four quarters ending in Mar'25, Dec'24, Sep'24, and Jun'24.<BR><BR>As of Dec'24, the balance sheet shows shareholder's funds of 1,837.11 million and total assets of 5,202.15 million.

Read More

What does The Ensign Group, Inc. do?

22-Jun-2025

The Ensign Group, Inc. specializes in healthcare services, focusing on skilled nursing and rehabilitative services. As of March 2025, it reported net sales of $1.173 billion and a net profit of $80 million, with a market cap of approximately $9.28 billion.

Overview:<BR>The Ensign Group, Inc. provides healthcare services, specializing in skilled nursing and rehabilitative services within the Pharmaceuticals & Biotechnology industry, and operates in the mid-cap market segment.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1,173 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 80 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 9,277.82 Million (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 30.00 <BR>Dividend Yield: 0.15% <BR>Debt Equity: -0.05 <BR>Return on Equity: 16.14% <BR>Price to Book: 4.82<BR><BR>Contact Details:<BR>Address: 29222 Rancho Viejo Rd Ste 127, SAN JUAN CAPISTRANO CA: 92675-1049 <BR>Tel: 1 949 4879500 <BR>Website: https://ensigngroup.net/

Read More

Should I buy, sell or hold The Ensign Group, Inc.?

22-Jun-2025

Who are in the management team of The Ensign Group, Inc.?

22-Jun-2025

As of March 2022, The Ensign Group, Inc.'s management team includes Co-Founder and Executive Chairman Christopher Christensen, CEO Barry Port, and several independent directors: Swati Abbott, Ann Blouin, Lee Daniels, and Daren Shaw. Roy Christensen serves as Chairman Emeritus.

As of March 2022, the management team of The Ensign Group, Inc. includes the following individuals:<BR><BR>- Mr. Christopher Christensen: Co-Founder, Executive Chairman, and the Chairman of the Board<BR>- Mr. Roy Christensen: Chairman Emeritus<BR>- Mr. Barry Port: Chief Executive Officer and Director<BR>- Ms. Swati Abbott: Independent Director<BR>- Dr. Ann Blouin: Independent Director<BR>- Mr. Lee Daniels: Independent Director<BR>- Mr. Daren Shaw: Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Read More

Is The Ensign Group, Inc. technically bullish or bearish?

20-Sep-2025

As of August 5, 2025, The Ensign Group, Inc. shows a bullish trend supported by strong technical indicators, outperforming the S&P 500 with a year-to-date return of 25.75%, despite some mixed signals in longer-term indicators.

As of 5 August 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view, including bullish MACD readings on both the weekly and monthly time frames, and a bullish daily moving average. The Bollinger Bands are showing a mildly bullish trend on both weekly and monthly charts. However, the KST is bullish weekly but mildly bearish monthly, and Dow Theory indicates a mildly bearish weekly stance while remaining bullish monthly. <BR><BR>In terms of performance, The Ensign Group, Inc. has outperformed the S&P 500 year-to-date with a return of 25.75% compared to the S&P's 12.22%, and over three years, it has returned 97.09% versus the S&P's 70.41%. Overall, the technical indicators suggest a strong bullish sentiment despite some mixed signals in the longer-term indicators.

Read More

Is The Ensign Group, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, The Ensign Group, Inc. is considered undervalued with an attractive valuation grade, featuring a P/E ratio of 30, an EV to EBITDA of 19.44, and a PEG ratio of 0.36, indicating potential growth compared to peers like Encompass Health Corp. and DaVita, Inc.

As of 17 October 2025, The Ensign Group, Inc. has moved from a very expensive valuation grade to attractive. Based on the current metrics, the company appears to be undervalued. Key valuation ratios include a P/E ratio of 30, an EV to EBITDA of 19.44, and a PEG ratio of 0.36, which suggests that the stock may offer growth potential relative to its price.<BR><BR>In comparison to peers, The Ensign Group's P/E ratio of 30 is higher than Encompass Health Corp.'s 20.94, but lower than its own previous valuation. The EV to EBITDA ratio of 19.44 is also more favorable than the risky DaVita, Inc.'s 7.56, indicating a stronger operational performance. Although return data is not available for a direct comparison with the S&P 500, the recent grade change and attractive valuation suggest a positive outlook for the stock.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Management Efficiency with a high ROE of 13.52%

 
2

Company has a low Debt to Equity ratio (avg) at times

 
3

Healthy long term growth as Net Sales has grown by an annual rate of 14.72% and Operating profit at 16.74%

 
4

The company has declared Positive results for the last 4 consecutive quarters

5

With ROE of 16.14%, it has a very expensive valuation with a 4.77 Price to Book Value

6

Market Beating performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 10,536 Million (Small Cap)

stock-summary
P/E

30.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.13%

stock-summary
Debt Equity

-0.08

stock-summary
Return on Equity

16.09%

stock-summary
Price to Book

5.22

Revenue and Profits:
Net Sales:
1,228 Million
(Quarterly Results - Jun 2025)
Net Profit:
84 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.71%
0%
6.71%
6 Months
14.89%
0%
14.89%
1 Year
23.18%
0%
23.18%
2 Years
57.3%
0%
57.3%
3 Years
83.3%
0%
83.3%
4 Years
130.46%
0%
130.46%
5 Years
135.32%
0%
135.32%

The Ensign Group, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
14.72%
EBIT Growth (5y)
16.74%
EBIT to Interest (avg)
28.64
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.05
Sales to Capital Employed (avg)
2.06
Tax Ratio
23.13%
Dividend Payout Ratio
4.74%
Pledged Shares
0
Institutional Holding
97.48%
ROCE (avg)
18.40%
ROE (avg)
13.52%
Valuation key factors
Factor
Value
P/E Ratio
30
Industry P/E
Price to Book Value
4.77
EV to EBIT
23.98
EV to EBITDA
19.44
EV to Capital Employed
4.98
EV to Sales
2.05
PEG Ratio
0.36
Dividend Yield
0.15%
ROCE (Latest)
20.77%
ROE (Latest)
16.14%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
Bullish
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 119 Schemes (55.75%)

Foreign Institutions

Held by 164 Foreign Institutions (9.04%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 18.48% vs 14.77% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 18.68% vs 11.08% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,227.80",
          "val2": "1,036.30",
          "chgp": "18.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "130.30",
          "val2": "106.60",
          "chgp": "22.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.00",
          "val2": "2.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.70",
          "val2": "-0.20",
          "chgp": "-250.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "84.50",
          "val2": "71.20",
          "chgp": "18.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "85.20%",
          "val2": "83.10%",
          "chgp": "0.21%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 16.26% vs 24.49% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 42.28% vs -6.63% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4,260.50",
          "val2": "3,664.60",
          "chgp": "16.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "445.30",
          "val2": "263.80",
          "chgp": "68.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "8.30",
          "val2": "8.10",
          "chgp": "2.47%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.90",
          "val2": "63.90",
          "chgp": "-104.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "298.50",
          "val2": "209.80",
          "chgp": "42.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "84.80%",
          "val2": "52.20%",
          "chgp": "3.26%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
1,227.80
1,036.30
18.48%
Operating Profit (PBDIT) excl Other Income
130.30
106.60
22.23%
Interest
2.00
2.00
Exceptional Items
-0.70
-0.20
-250.00%
Consolidate Net Profit
84.50
71.20
18.68%
Operating Profit Margin (Excl OI)
85.20%
83.10%
0.21%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 18.48% vs 14.77% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 18.68% vs 11.08% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
4,260.50
3,664.60
16.26%
Operating Profit (PBDIT) excl Other Income
445.30
263.80
68.80%
Interest
8.30
8.10
2.47%
Exceptional Items
-2.90
63.90
-104.54%
Consolidate Net Profit
298.50
209.80
42.28%
Operating Profit Margin (Excl OI)
84.80%
52.20%
3.26%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 16.26% vs 24.49% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 42.28% vs -6.63% in Dec 2023

stock-summaryCompany CV
About The Ensign Group, Inc. stock-summary
stock-summary
The Ensign Group, Inc.
Pharmaceuticals & Biotechnology
Ensign Group, Inc., through its operating subsidiaries, provides healthcare services. The Company's operating subsidiaries provide a spectrum of skilled nursing services, physical, occupational and speech therapies and other rehabilitative and healthcare services. The Company operates approximately 231 healthcare operations, 24 of which also include assisted living operations across thirteen states. It operates the healthcare facilities across Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. Through its skilled nursing operations, the Company provides short stay patients and long stay patients with a range of medical, nursing, rehabilitative, pharmacy and routine services, including daily dietary, social and recreational services.
Company Coordinates stock-summary
Company Details
29222 Rancho Viejo Rd Ste 127 , SAN JUAN CAPISTRANO CA : 92675-1049
stock-summary
Tel: 1 949 4879500
stock-summary
Registrar Details